MPLT MapLight Therapeutics, Inc.
Financings ·
MapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales.
MapLight agreed to sell 9,197,887 voting shares at $11.38 and pre-funded warrants for 3,983,168 more shares, for about $150.0 million gross before fees.
MapLight reported $351.3 million in cash and investments at June 30, 2026 and cited funding through 2028. It also agreed to a private placement of about $150.0 million at $11.38 a share. Six-month operating cash use was $96.0 million.
The Danish investor sold 1.6 million shares in open-market trades at $12.00 to $15.00 and reported 2,086,622 shares left, about 4.9%.
The 2025 financing closed in two parts before the IPO. Holders tied to board members were among the buyers, the proxy shows.
MapLight Therapeutics closed its initial public offering at $17.00 a share, and the underwriters exercised their option for more shares in full. Its lead drug has no Phase 2 results yet.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $138.3 million | $68.5 million |
| Net income (loss) | -$161.2 million | -$77.6 million |
| Cash from operations | -$138.1 million | -$78.8 million |
| Cash and equivalents | $46.7 million | $38.3 million |
| Short-term investments | $258.4 million | $70.5 million |
Opinion Medium conviction
At $7.97 a share, MapLight trades at roughly the cash we estimate it holds, so investors pay little for a schizophrenia drug with one moderate Phase 2 win that still needs a second trial. We rate the shares Outperform.
Our latest story on this, dated Mar 26, 2026: "MapLight annual report details $200 million Series D preferred financing". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 13, 2026: "MapLight agrees $150 million private placement of shares and pre-funded warrants". The story links the filing or release it is based on. Read the story.
MapLight Therapeutics, Inc. trades under the ticker MPLT on NASDAQ.
MapLight Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for MapLight Therapeutics, Inc. is 1770069. Its filings are on SEC EDGAR.
42,436,326 shares as of 2026-03-19, per the cover page of its 10-K filed 2026-03-26.
Our directory records MapLight Therapeutics, Inc. under United States.
Our directory classifies MapLight Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MapLight Therapeutics, Inc. is US56565P1030.
aibio.space lists MapLight Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
MapLight Therapeutics, Inc. reported a net loss of $161.2 million for the fiscal year ended Dec 31, 2025, and used $138.1 million of cash in operations, per its annual report to the SEC.
$138.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$304.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on MapLight Therapeutics, dated Sep 23, 2026: "MapLight resale registration for 13.2 million private-placement shares takes effect". MapLight's resale prospectus lets the investors in its $150.0 million August placement sell up to 13,181,055 shares. The company receives no proceeds from those sales. Source.
The SEC declared the selling-stockholder registration effective. Source
The later resale prospectus confirms the private placement closed. Source
MapLight agreed a private placement with common shares and pre-funded warrants. Source
Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,9.01). Source
The company reported its CFO separation and appointed an interim CFO; it said the separation was unrelated to financial-reporting concerns. Source
The underwriters full additional-share option settled. Source
The IPO initial closing and a concurrent private placement closed; the private share count is unreconciled. Source
MapLight signed underwriting and concurrent private-placement purchase agreements. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
MapLight entered a Series D purchase agreement; the annual report records $200 million gross issued during the year. Source
The latest quarterly cover identifies the Nasdaq Global Select Market and the MPLT symbol. Source
The company reported approximately $351.3 million at 2026-06-30, including investments. This is not a cash-only figure. Source
The quarterly report projected funding through 2028, including expected placement proceeds and subject to operating assumptions. Source
The later resale prospectus says the private placement closed on 2026-08-14. Source
Yes. The financing included pre-funded warrants in lieu of common shares for certain purchasers. The exact later unexercised balance is not verified. Source
No. The prospectus states that the issuer will not receive proceeds from selling-stockholder sales. Source
The filings describe a one-for-16.8 common-stock consolidation in 2025-10. Source
The annual audit is signed by RSM US LLP, which says it has served since 2020. Source
Novo Holdings A/S reported that it ceased to own more than five percent on 2026-07-30. That is a dated filing position, not a current holding certification. Source
No. The selling-stockholder table is hypothetical and assumes covered shares are sold; registration does not prove a sale occurred. Source
That is a research limit rather than a guarantee of future listing compliance. Source
The report includes a going-concern discussion and says resources cover at least twelve months. No substantial doubt phrase was found; this is not a financial-safety assurance. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio